Healthcare Publications Human Vaccines Market | Page 2

The market’s trends include strong research pipeline under which number of novel vaccines
are being developed such as rubella vaccine, ebola vaccine etc. DNA recombinant
technology is also a common technology used in the development of novel acting vaccines.
Taking all the factors into consideration, we expect the Middle East and Africa human
vaccines market which was $ 2.8 billion in 2015 to reach around $ 5.46 billion in future,
growing at a CAGR of 11.8%.
Study Objectives Middle East and Africa Human Vaccines Market:

To provide detail analysis of the market structure along with forecast for the next 6
years of various segments and sub-segments of the Middle East and Africa human
vaccines market.
 To provide insights about factors affecting the market growth.
 To analyze the market based on various analyses which includes price analysis,
supply chain analysis, Porters Five Force analysis etc.
 To provide past and estimated future revenue of the market’s segments and sub-
segments with respect to the Middle East and Africa human vaccines market.
 To provide country level analysis of the market with respect to the current market
size and future growth prospect.
 To provide country level analysis of the market for segments which includes by
technology, by disease indication, by type, by composition, by end user, by route of
administration and other sub segments. To provide overview of key players and their
strategic profiling in the market, comprehensively analyzing their core competencies,
and drawing a competitive landscape of the market
 To track and analyze competitive developments such as joint ventures, strategic
alliances, mergers and acquisitions, new product developments along with research
and developments globally.
Middle East and Africa Human Vaccines Market, by Technology, 2015 (%)
Intended Audience

Vaccines manufacturers